Barb only please

90904

Access DB# _____

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Dwayne C. Jones Examiner #: 71279 Date: 4/22/03
Art Unit: 1619 Phone Number 30 8-1654 Serial Number: 10/[illegible]
Mail Box and Bldg/Room Location: 2007, CM1 Results Format Preferred (circle): PAPER DISK E-MAIL
2007 CM1

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: See attached sheet

Inventors (please provide full names): "

"

Earliest Priority Filing Date: "

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Please search claims 1, 7 and 22.

Point of Contact:
Barb O'Bryen
Technical Information Specialist
STIC CM1 6A05 308-4291

****

STAFF USE ONLY	Type of Search	Vendors and cost where applicable
Searcher: B.O'B	NA Sequence (#) _____	STN 488
Searcher Phone #: _____	AA Sequence (#) _____	Dialog _____
Searcher Location: _____	Structure (#) 2	Questel/Orbit _____
Date Searcher Picked Up: _____	Bibliographic _____	Dr.Link _____
Date Completed: 4-23-03	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: 20	Fulltext _____	Sequence Systems _____
Clerical Prep Time: _____	Patent Family _____	WWW/Internet _____
Online Time: 24	Other _____	Other (specify) _____

PTO-1590 (8-01)

=> fil reg; d stat que l6; fil capl; d que nos l15; fil uspatf; d que nos l19
FILE 'REGISTRY' ENTERED AT 15:21:25 ON 23 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 22 APR 2003 HIGHEST RN 503805-80-9
DICTIONARY FILE UPDATES: 22 APR 2003 HIGHEST RN 503805-80-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

L4 STR



this structure encompasses structures of claims 1, 7, & 22

NODE ATTRIBUTES:
CONNECT IS M3 RC AT 7 - carbon at node 7 is connected to at least 3 non-hydrogen atoms
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE
L6 1165 SEA FILE=REGISTRY SSS FUL L4

100.0% PROCESSED 3685 ITERATIONS 1165 ANSWERS
SEARCH TIME: 00.00.01

FILE 'CAPLUS' ENTERED AT 15:21:25 ON 23 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Apr 2003 VOL 138 ISS 17
FILE LAST UPDATED: 22 Apr 2003 (20030422/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

claims 1 & 7

```
L4              STR
L6          1165 SEA FILE=REGISTRY SSS FUL L4
L7           255 SEA FILE=CAPLUS ABB=ON  L6
L10         4300 SEA FILE=CAPLUS ABB=ON  ALOPEC?
L11        52397 SEA FILE=CAPLUS ABB=ON  HAIR#
L12         2199 SEA FILE=CAPLUS ABB=ON  BALD####
L13         5737 SEA FILE=CAPLUS ABB=ON  HIRSUT?
L14          104 SEA FILE=CAPLUS ABB=ON  HYPERTRICHOSIS
L15            3 SEA FILE=CAPLUS ABB=ON  L7 AND (L10 OR L11 OR L12 OR L13 OR
                 L14)
```

FILE 'USPATFULL' ENTERED AT 15:21:25 ON 23 APR 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 22 Apr 2003 (20030422/PD)
FILE LAST UPDATED: 22 Apr 2003 (20030422/ED)
HIGHEST GRANTED PATENT NUMBER: US6553568
HIGHEST APPLICATION PUBLICATION NUMBER: US2003074707
CA INDEXING IS CURRENT THROUGH 22 Apr 2003 (20030422/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 22 Apr 2003 (20030422/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2003
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2003

>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate

substance identification.

```
L4                STR
L6           1165 SEA FILE=REGISTRY SSS FUL L4
L16            85 SEA FILE=USPATFULL ABB=ON  L6
L17         62760 SEA FILE=USPATFULL ABB=ON  HAIR# OR BALD#### OR ALOPEC? OR
                  HIRSUT? OR HYPERTRICHOSIS
L18          5853 SEA FILE=USPATFULL ABB=ON  (HAIR# OR BALD#### OR ALOPEC? OR
                  HIRSUT? OR HYPERTRICHOSIS)/IT
L19            11 SEA FILE=USPATFULL ABB=ON  L16 AND (L17 OR L18)

=> fil medl drugu biosis toxcenter embase; d que nos l22
FILE 'MEDLINE' ENTERED AT 15:21:32 ON 23 APR 2003

FILE 'DRUGU' ENTERED AT 15:21:32 ON 23 APR 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'BIOSIS' ENTERED AT 15:21:32 ON 23 APR 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'TOXCENTER' ENTERED AT 15:21:32 ON 23 APR 2003
COPYRIGHT (C) 2003 ACS

FILE 'EMBASE' ENTERED AT 15:21:32 ON 23 APR 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

L4                STR
L6           1165 SEA FILE=REGISTRY SSS FUL L4
L20           688 SEA L6
L21        221527 SEA (HAIR# OR BALD#### OR ALOPEC? OR HIRSUT? OR HYPERTRICHOSIS)

L22             10 SEA L20 AND L21

=> dup rem l15,l19,l22
FILE 'CAPLUS' ENTERED AT 15:21:39 ON 23 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:21:39 ON 23 APR 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 15:21:39 ON 23 APR 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.
PROCESSING COMPLETED FOR L15
PROCESSING COMPLETED FOR L19
PROCESSING COMPLETED FOR L22
L23             24 DUP REM L15 L19 L22 (0 DUPLICATES REMOVED)
                   ANSWERS '1-3' FROM FILE CAPLUS
                   ANSWERS '4-14' FROM FILE USPATFULL
                   ANSWERS '15-24' FROM FILE EMBASE

=> d ibib abs hitstr 1-14; d iall 15-24

L23 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER:         2002:89809 CAPLUS
DOCUMENT NUMBER:          136:139844
TITLE:                    Compositions useful for regulating hair
                          growth containing metal complexes of oxidized
```

carbohydrates

INVENTOR(S): Gardlik, John Michael; Severynse-Stevens, Diana; Comstock, Bryan Gabriel

PATENT ASSIGNEE(S): The Procter & Gamble Company, USA

SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002007700	A2	20020131	WO 2001-US23425	20010725

W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002119174	A1	20020829	US 2001-909440	20010719

PRIORITY APPLN. INFO.: US 2000-220756P P 20000726

AB A stable cosmetic, dermatol., or pharmaceutical compn. comprising: (a) about 0.001-99.9%, by wt., of at least one metal complex of an oxidized carbohydrate, wherein the metal complex of an oxidized carbohydrate is neither zinc gluconate, manganese gluconate, nor lithium gluconate; and (b) about 0.1-99.999%, by wt., of a vehicle, wherein the vehicle comprises at least about 5%, by wt. of the compn., of propylene glycol. The compn. is administered orally, parenterally or topically. For example, a topical compn. was prepd. contg. zinc lactobionate 5.0%, zinc gluconate 3.0%, minoxidil 2.5%, propylene glycol 8.0%, dimethylisosorbide 19.0%, and ethanol and minors up to 100%.

IT **120210-48-2**, Tenidap
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. contg. metal complexes of oxidized carbohydrates for regulating **hair** growth)

RN 120210-48-2 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L23 ANSWER 2 OF 24 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:89795 CAPLUS
DOCUMENT NUMBER: 136:139843
TITLE: Method of regulating **hair** growth using metal complexes of oxidized carbohydrates
INVENTOR(S): Gardlik, John Michael; Severynse-Stevens, Diana; Comstock, Bryan Gabriel
PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002007685	A2	20020131	WO 2001-US23424	20010725
W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002035070	A1	20020321	US 2001-909441	20010719

PRIORITY APPLN. INFO.: US 2000-220755P P 20000726

AB A method for regulating the growth of **hair** comprising administering to a mammal, an effective amt. of a compn. comprising: (a) about 0.001-99.9%, by wt., of at least one metal complex of an oxidized carbohydrate, wherein the metal complex of an oxidized carbohydrate is neither zinc gluconate nor manganese gluconate; and (b) about 0.1-99.999%, by wt., of a vehicle. The compn. is administered orally, parenterally, or topically. For example, a topical compn. contained zinc lactobionate 5.0%, zinc gluconate 1.0%, zinc pyrithione 1.0%, Tween 20 1.0%, propylene glycol 10.0%, dimethylisosorbide 18.0%, EtOH 30.0%, and water and minors up to 100%. Also, tablets were prepd. contg. zinc lactobionate 100 mg, Crospovidone 15 mg, lactose 200 mg, microcryst. cellulose 80 mg, and magnesium stearate 5 mg.

IT **120210-48-2**, Tenidap
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. contg. metal complexes of oxidized carbohydrates for regulating **hair** growth)

RN 120210-48-2 CAPLUS
CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L23 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:319664 CAPLUS
DOCUMENT NUMBER: 134:320886
TITLE: Methods using indoline compounds for treating **hair** loss
INVENTOR(S): Lammers, Karen Marie
PATENT ASSIGNEE(S): The University of Texas Southwestern Medical Center, USA
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001030151	A1	20010503	WO 2000-US41383	20001020
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1223809	A1	20020724	EP 2000-984592	20001020
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003512396	T2	20030402	JP 2001-532591	20001020

PRIORITY APPLN. INFO.: US 1999-161577P P 19991026
WO 2000-US41383 W 20001020

OTHER SOURCE(S): MARPAT 134:320886
GI

applicant's priority



I



II

AB Methods and compns. are provided for treating **hair** loss in mammals, including arresting **hair** loss, reversing **hair** loss and/or promoting **hair** growth. The methods comprise administering a compn. wherein the compn. comprises an indoline compd. I [X = H, F, Cl, Br, nitro, cyano, thio, C1-6 alkyl, etc; Y = H, F, Cl, Br, C1-4 alkyl, etc; R1 = C1-6 alkyl, C3-7 cycloalkyl, (substituted) Ph, etc.] or II [X = H, F, Cl, Br, nitro, cyano, thio, C1-6 alkyl, etc; Y = H, F, Cl, Br, C1-4 alkyl, etc; R = C2-10 alkanoyl, C7-10 phenylalkanoyl, C2-10 alkoxycarbonyl, etc.; R1 = C1-6 alkyl, C3-7 cycloalkyl, (substituted) Ph, etc.], or a pharmaceutically acceptable salt, hydrate, tautomer, or biohydrolyzable amide, or ester thereof.

IT **100599-27-7 154741-15-8D**, O-alkyl and O-alkanoyl derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(indoline compds. for treating **hair** loss)

RN 100599-27-7 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-2-oxo-3-(2-thienylcarbonyl)- (9CI) (CA INDEX NAME)



RN 154741-15-8 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo- (9CI) (CA INDEX NAME)



IT **119784-94-0**, Tenidap sodium **120210-48-2**, Tenidap
120210-48-2D, Tenidap, pro-form **336609-78-0**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(indoline compds. for treating **hair** loss, and use with other agents)

RN 119784-94-0 CAPLUS
CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-, monosodium salt, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● Na

RN 120210-48-2 CAPLUS
CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 120210-48-2 CAPLUS
CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 336609-78-0 CAPLUS
CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-2-oxo-3-(2-thienylcarbonyl)-, mixt. with 6-(1-piperidinyl)-2,4-pyrimidinediamine 3-oxide (9CI) (CA INDEX NAME)

CM 1

CRN 100599-27-7
CMF C14 H9 Cl N2 O3 S



CM 2

CRN 38304-91-5
CMF C9 H15 N5 O



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 4 OF 24 USPATFULL
ACCESSION NUMBER: 2003:4104 USPATFULL
TITLE: Use of NSAIDs for prevention and treatment of cellular abnormalities of the female reproductive tract
INVENTOR(S): Prior, Christopher P., Rosemont, PA, UNITED STATES
Eisen, Drore, Cincinnati, OH, UNITED STATES

Searched by Barb O'Bryen, STIC 308-4291

Herlands, Louis, Cambridge, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003004143	A1	20030102
APPLICATION INFO.:	US 2002-125218	A1	20020418 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-284756P	20010418 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CHERYL H AGRIS PHD, PO BOX 806, PELHAM, NY, 10803
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
LINE COUNT: 583
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is directed to uses of non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment and prevention of cellular abnormalities of the female reproductive tract.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **120210-48-2**, Tenidap
(NSAIDS for prevention and treatment of cellular abnormalities of the female reproductive tract)
RN 120210-48-2 USPATFULL
CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



different use + bad Tel

L23 ANSWER 5 OF 24 USPATFULL
ACCESSION NUMBER: 2003:4103 USPATFULL
TITLE: Use of NSAIDs for prevention and treatment of cellular abnormalities of the lung or bronchial pathway
INVENTOR(S): Prior, Christopher P., Rosemont, PA, UNITED STATES
Eisen, Drore, Cincinnati, OH, UNITED STATES
Herlands, Louis, Cambridge, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003004142	A1	20030102
APPLICATION INFO.:	US 2002-124893	A1	20020417 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-284731P	20010418 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CHERYL H AGRIS PHD, PO BOX 806, PELHAM, NY, 10803
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 570
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention is directed to uses of non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment and prevention of cellular abnormalities of the lung or bronchial pathway.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **120210-48-2**, Tenidap
(NSAIDS for prevention and treatment of cellular abnormalities of the lung or bronchial pathway)
RN 120210-48-2 USPATFULL
CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L23 ANSWER 6 OF 24 USPATFULL
ACCESSION NUMBER: 2002:259457 USPATFULL
TITLE: Immunosuppresive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
INVENTOR(S): Gregory, Susan A., St. Louis, MO, UNITED STATES
Isakson, Peter C., Clarkson Valley, MO, UNITED STATES
Anderson, Gary, Maryland Heights, MO, UNITED STATES
PATENT ASSIGNEE(S): G.D. Searle & Co.

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002143033	A1	20021003
APPLICATION INFO.:	US 2002-98644	A1	20020315 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-430072, filed on 18 Oct 1999, GRANTED, Pat. No. US 6376528 Continuation of Ser. No. US 1998-189463, filed on 10 Nov 1998, ABANDONED Continuation of Ser. No. US 1996-600622, filed on 13 Feb 1996, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SENNIGER POWERS LEAVITT AND ROEDEL, ONE METROPOLITAN SQUARE, 16TH FLOOR, ST LOUIS, MO, 63102
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 1613

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is in the field of a combination comprising a therapeutically-effective amount of a cyclooxygenase-2 inhibitor, a 5-lipoxygenase inhibitor and an immunosuppressive drug selected from antiproliferative agents, antiinflammatory-acting compounds and inhibitors of leukocyte activation. This combination may be used, for example, to suppress the immune response associated with organ transplantation, graft versus host disease, and conditions with underlying autoimmune or inflammatory reactivities or responses.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **120210-48-2**, Tenidap
(cyclooxygenase-2 and 5-lipoxygenase inhibitor combinations with immunosuppressive effects)
RN 120210-48-2 USPATFULL
CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L23 ANSWER 7 OF 24 USPATFULL
ACCESSION NUMBER: 2002:221039 USPATFULL
TITLE: Compositions useful for regulating **hair** growth containing metal complexes of oxidized carbohydrates
INVENTOR(S): Gardlik, John Michael, Cincinnati, OH, UNITED STATES
Severynse-Stevens, Diana, Yardley, PA, UNITED STATES
Comstock, Bryan Gabriel, Mason, OH, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002119174	A1	20020829	
APPLICATION INFO.:	US 2001-909440	A1	20010719	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-220756P	20000726 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: THE PROCTER & GAMBLE COMPANY, PATENT DIVISION, SHARON WOODS TECHINICAL CENTER, 11511 REED HARTMAN HIGHWAY, CINCINNATI, OH, 45241
NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 1
LINE COUNT: 3342
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A stable cosmetic, dermatological, or pharmaceutical composition

comprising: (a) from about 0.001% to about 99.9%, by weight, of at least one metal complex of an oxidized carbohydrate; wherein the metal complex of an oxidized carbohydrate is neither zinc gluconate nor manganese gluconate nor lithium gluconate; and (b) from about 0.1% to about 99.999%, by weight, of a vehicle, wherein the vehicle comprises at least about 5%, by weight of the composition, of propylene glycol.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **120210-48-2**, Tenidap
(compns. contg. metal complexes of oxidized carbohydrates for regulating **hair** growth)
RN 120210-48-2 USPATFULL
CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L23 ANSWER 8 OF 24 USPATFULL
ACCESSION NUMBER: 2002:61235 USPATFULL
TITLE: Method of regulating **hair** growth using metal complexes of oxidized carbohydrates
INVENTOR(S): Gardlik, John Michael, Cincinnati, OH, UNITED STATES
Severynse-Stevens, Diana, Yardley, PA, UNITED STATES
Comstock, Bryan Gabriel, Mason, OH, UNITED STATES
PATENT ASSIGNEE(S): The Procter & Gamble Company (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002035070	A1	20020321	
APPLICATION INFO.:	US 2001-909441	A1	20010719	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-220755P	20000726 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Brent M. Peebles, The Procter & Gamble Company, Sharon Woods Technical Center, 11511 Reed Hartman Highway, Cincinnati, OH, 45241
NUMBER OF CLAIMS: 44
EXEMPLARY CLAIM: 1
LINE COUNT: 3276
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for regulating the growth of **hair** comprising administering to a mammal, an effective amount of a composition comprising: (a) from about 0.001% to about 99.9%, by weight, of at least one metal complex of an oxidized carbohydrate, wherein the metal complex

of an oxidized carbohydrate is neither zinc gluconate nor manganese gluconate; and (b) from about 0.1% to about 99.999%, by weight, of a vehicle.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **120210-48-2**, Tenidap
(compns. contg. metal complexes of oxidized carbohydrates for regulating **hair** growth)
RN 120210-48-2 USPATFULL
CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L23 ANSWER 9 OF 24 USPATFULL

ACCESSION NUMBER:	2002:102081 USPATFULL			
TITLE:	Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a NSAID			
INVENTOR(S):	Artman, Linda D., Salt Lake City, UT, United States Balandrin, Manuel F., Sandy, UT, United States			
PATENT ASSIGNEE(S):	NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6383527	B1	20020507	
	WO 9944623		19990910	
APPLICATION INFO.:	US 2001-623384		20010222	(9)
	WO 1999-US4786		19990304	
			20000901	PCT 371 date
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	GRANTED			
PRIMARY EXAMINER:	Reamer, James H.			
LEGAL REPRESENTATIVE:	Foley & Lardner			
NUMBER OF CLAIMS:	39			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)			
LINE COUNT:	858			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Preparations and extracts of valerian, as well as isovaleramide, isovaleric acid, and its pharmaceutically acceptable salts, esters, and substituted amides, and other valerian-related compounds, in combination with NSAIDs exhibit clinically significant pharmacological properties which implicate a treatment for acute muscular aches, strains, and sprains which occur from a localized, external insult to a particular muscle or muscle group outside of, or peripheral to, the CNS. The compositions in question generally are non-cytotoxic and do not elicit

weakness or sedative activity at doses that are effective for the symptomatic treatment of such pathological conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **120210-48-2**, Tenidap
(isovaleric acid deriv. and NSAID combinations for treatment of muscle pain and inflammation)
RN 120210-48-2 USPATFULL
CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L23 ANSWER 10 OF 24 USPATFULL

ACCESSION NUMBER:	2002:88511 USPATFULL
TITLE:	Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
INVENTOR(S):	Gregory, Susan A, St. Louis, MO, United States Isakson, Peter C, Clarkson Valley, MO, United States Anderson, Gary, Maryland Heights, MO, United States
PATENT ASSIGNEE(S):	G. D. Searle & Co., Chicago, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6376528	B1	20020423
APPLICATION INFO.:	US 1999-430072		19991018 (9)

RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-189463, filed on 10 Nov 1998, now abandoned Continuation of Ser. No. US 1996-600622, filed on 13 Feb 1996, now abandoned
DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Seaman, D. Margaret
LEGAL REPRESENTATIVE:	Senniger, Powers, Leavitt & Roedel
NUMBER OF CLAIMS:	9
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT:	1629

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method to suppress immune, acute or delayed-type hypersensitivity by treatment with a combination of a therapeutically-effective amount of a 5-lipoxygenase inhibitor and a cyclooxygenase-2 inhibitor is reported. The method may be used, for example, to suppress the immune response associated with organ transplantation, graft versus host disease, and conditions with underlying autoimmune or inflammatory reactivities or responses.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **120210-48-2**, Tenidap
(cyclooxygenase-2 and 5-lipoxygenase inhibitor combinations with immunosuppressive effects)
RN 120210-48-2 USPATFULL
CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L23 ANSWER 11 OF 24 USPATFULL

ACCESSION NUMBER:	2000:174665 USPATFULL
TITLE:	Peripherally active anti-hyperalgesic opiates
INVENTOR(S):	Yaksh, Tony L., San Diego, CA, United States
PATENT ASSIGNEE(S):	Regents of the Univ. of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6166039		20001226
APPLICATION INFO.:	US 1998-199873		19981124 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-528510, filed on 12 Sep 1995, now patented, Pat. No. US 5849761		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Spivack, Phyllis G.		
LEGAL REPRESENTATIVE:	Seidman, Stephanie L.Heller Ehrman White and McAuliffe LLP		
NUMBER OF CLAIMS:	22		
EXEMPLARY CLAIM:	1		
LINE COUNT:	3758		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for treatment of peripheral hyperalgesia are provided, comprising administering compositions containing an anti-hyperalgesia effective amount of one or more compounds that directly or indirectly interact with peripheral opiate receptors, but that do not, upon topical or local administration, elicit central nervous system side effects. The anti-diarrheal compound 4-(.rho.-chlorophenyl)-4-hydroxy-N-N-dimethyl-.alpha.,.alpha.-diphenyl-1-piperidinebutyramide hydrochloride is preferred for use in the methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **120210-48-2**, Tenidap
(peripherally active anti-hyperalgesic opiates)
RN 120210-48-2 USPATFULL
CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-3-(hydroxy-2-

thienylmethylene)-2-oxo-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L23 ANSWER 12 OF 24 USPATFULL
ACCESSION NUMBER: 1999:153297 USPATFULL
TITLE: Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx
INVENTOR(S): Cavanaugh, Jr., Paul Francis, Cincinnati, OH, United States
PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 36419		19991130	
	US 5626838		19970506	(Original)
APPLICATION INFO.:	US 1998-49329		19980327	(9)
	US 1995-402587		19950313	(Original)

DOCUMENT TYPE: Reissue
FILE SEGMENT: Granted
PRIMARY EXAMINER: Krass, Frederick
LEGAL REPRESENTATIVE: White, Loy M., Mohl, Douglas C., Reed, T. David
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 9
LINE COUNT: 715
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel methods for prevention or treatment of primary and recurring squamous cell carcinoma of the oral cavity or oropharynx comprising topical administration, to the oral cavity or oropharynx, of an effective amount of an NSAID, especially a composition administering from about 0.001% to about 0.2% ketorolac to the oral cavity, alone or as an adjunct to surgery and/or radiation therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **120210-48-2**, Tenidap
(nonsteroidal anti-inflammatory drugs for treatment of squamous cell carcinomas of oral cavity or oropharynx)
RN 120210-48-2 USPATFULL
CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L23 ANSWER 13 OF 24 USPATFULL
ACCESSION NUMBER: 1998:157363 USPATFULL
TITLE: Peripherally active anti-hyperalgesic opiates
INVENTOR(S): Yaksh, Tony L., San Diego, CA, United States
PATENT ASSIGNEE(S): Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5849761		19981215
APPLICATION INFO.:	US 1995-528510		19950912 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Spivack, Phyllis G.
LEGAL REPRESENTATIVE: Seidman, Stephanie L.Heller Ehrman White & McAuliffe
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 3472
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods using compositions for the treatment of peripheral hyperalgesia are provided. The compositions contain an anti-hyperalgesia effective amount of one or more compounds that directly or indirectly interact with peripheral opiate receptors, but that do not, upon topical or local administration, elicit central nervous system side effects. The anti-diarrheal compound 4-(p-chlorophenyl)-4-hydroxy-N-N-dimethyl-.alpha.,.alpha.-diphenyl-1-piperidinebutyramide hydrochloride is preferred for use in the compositions of the claimed methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **120210-48-2**, Tenidap
(peripherally active anti-hyperalgesic opiates)
RN 120210-48-2 USPATFULL
CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L23 ANSWER 14 OF 24 USPATFULL
ACCESSION NUMBER: 97:38185 USPATFULL
TITLE: Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx
INVENTOR(S): Cavanaugh, Jr., Paul F., Cincinnati, OH, United States
PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5626838		19970506
APPLICATION INFO.:	US 1995-402587		19950313 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Krass, Frederick
LEGAL REPRESENTATIVE: Mohl, Douglas C., Poland, Mary Catherine, Rasser, Jacobus C.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 683
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel methods for prevention or treatment of primary and recurring squamous cell carcinoma of the oral cavity or oropharynx comprising topical administration, to the oral cavity or oropharynx, of an effective amount of an NSAID, especially a composition administering from about 0.001% to about 0.2% ketorolac to the oral cavity, alone or as an adjunct to surgery and/or radiation therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **120210-48-2**, Tenidap
(nonsteroidal anti-inflammatory drugs for treatment of squamous cell carcinomas of oral cavity or oropharynx)
RN 120210-48-2 USPATFULL
CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L23 ANSWER 15 OF 24 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 97082040 EMBASE
DOCUMENT NUMBER: 1997082040
TITLE: Drug treatment of rheumatic diseases in the 1990s: Achievements and future developments.
AUTHOR: Choy E.H.S.; Scott D.L.
CORPORATE SOURCE: Dr. D.L. Scott, Clinical and Academic Rheumatology, King's College Hospital (Dulwich), East Dulwich Grove, London SE22 8PT, United Kingdom
SOURCE: Drugs, (1997) 53/3 (337-348).
Refs: 91
ISSN: 0012-6667 CODEN: DRUGAY
COUNTRY: New Zealand
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 006 Internal Medicine
030 Pharmacology
031 Arthritis and Rheumatism
033 Orthopedic Surgery
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ABSTRACT:
There have been several advances in the therapy of arthritis. These are based on better understanding of the pathogenesis of rheumatic diseases, re-evaluation of previous therapeutic concepts such as combination therapy, and developments within biotechnology. There are 4 main areas of development, mainly involving the treatment of inflammatory synovitis. The first is with anti-inflammatory drugs, where there has been a focus on reducing gastrointestinal toxicity through the use of combination preparations such as diclofenac-misoprostol, and the introduction of drugs with more selectivity for cyclo-oxygenase-2 inhibition such as meloxicam. An additional approach has been the development of anti-inflammatory drugs such as tenidap which also control cytokine metabolism. The second area is slow-acting antirheumatic drugs with the introduction of cyclosporin as a single agent or in combination with methotrexate, the development of immunomodulating drugs such as leflunomide, and the demonstration that some antibiotics such as minocycline have slow-acting effects. The third area is the use of corticosteroids including the development of deflazacort as a bone sparing agent, the greater use of intramuscular depot steroids and the validation of low-dose oral corticosteroids in early rheumatoid arthritis. Finally, there have been advances in the biotechnology area with the demonstration that cytokine immunotherapy such as antibodies to tumour necrosis factor can rapidly improve

the symptoms of rheumatoid arthritis, and that T cell immunotherapy with antibodies to the CD4 receptor may be effective in reducing synovitis. Many of these agents have not yet been introduced into clinical practice but they show the diversity of drug development and suggest the likelihood of major therapeutic benefits in the next few years.

CONTROLLED TERM:

Medical Descriptors:
*arthritis: DT, drug therapy
*rheumatic disease: DT, drug therapy
alopecia: SI, side effect
antiinflammatory activity
article
biotechnology
bone atrophy: SI, side effect
cellular immunity
clinical trial
controlled study
drug selectivity
gastrointestinal symptom: SI, side effect
human
hypertension: SI, side effect
immunomodulation
major clinical study
meta analysis
nephrotoxicity: SI, side effect
osteoporosis: SI, side effect
rheumatoid arthritis: DT, drug therapy
synovitis: DT, drug therapy
t lymphocyte
vertigo: SI, side effect
Drug Descriptors:
*antiinflammatory agent: AE, adverse drug reaction
*antiinflammatory agent: CT, clinical trial
*antiinflammatory agent: DT, drug therapy
*antirheumatic agent: CT, clinical trial
*antirheumatic agent: DV, drug development
*antirheumatic agent: DT, drug therapy
antibiotic agent: CT, clinical trial
antibiotic agent: DT, drug therapy
cd4 antigen: EC, endogenous compound
corticosteroid: AE, adverse drug reaction
corticosteroid: CT, clinical trial
corticosteroid: AD, drug administration
corticosteroid: DO, drug dose
corticosteroid: DT, drug therapy
cyclooxygenase 2 inhibitor: PD, pharmacology
cyclosporin: CT, clinical trial
cyclosporin: AE, adverse drug reaction
cyclosporin: PR, pharmaceutics
cyclosporin: DT, drug therapy
cyclosporin: CB, drug combination
cyclosporin a: AE, adverse drug reaction
cyclosporin a: CT, clinical trial
cyclosporin a: DT, drug therapy
cyclosporin a: PR, pharmaceutics
cytokine: EC, endogenous compound
deflazacort: DT, drug therapy
deflazacort: CT, clinical trial
deflazacort: AE, adverse drug reaction
diclofenac: DT, drug therapy
diclofenac: CB, drug combination
immunoglobulin g: CT, clinical trial
immunoglobulin g: DO, drug dose

immunoglobulin g: DT, drug therapy
immunoglobulin g: PD, pharmacology
leflunomide: PD, pharmacology
leflunomide: DT, drug therapy
leflunomide: CT, clinical trial
leflunomide: AE, adverse drug reaction
meloxicam: PD, pharmacology
meloxicam: DT, drug therapy
meloxicam: CT, clinical trial
meloxicam: AE, adverse drug reaction
methotrexate: CT, clinical trial
methotrexate: CB, drug combination
methotrexate: DT, drug therapy
minocycline: DT, drug therapy
minocycline: CT, clinical trial
misoprostol: CB, drug combination
misoprostol: DT, drug therapy
monoclonal antibody: DV, drug development
monoclonal antibody: CT, clinical trial
nabumetone: CT, clinical trial
nabumetone: DT, drug therapy
nabumetone: AE, adverse drug reaction
nonsteroid antiinflammatory agent: DT, drug therapy
nonsteroid antiinflammatory agent: AE, adverse drug reaction
recombinant interleukin 1 receptor blocking agent: DV, drug development
rifampicin: CT, clinical trial
rifampicin: DT, drug therapy
tenidap: AE, adverse drug reaction
tenidap: CT, clinical trial
tenidap: DT, drug therapy
tenidap: PD, pharmacology
tumor necrosis factor antibody: DT, drug therapy

CAS REGISTRY NO.: (cyclosporin) 79217-60-0; (cyclosporin a) 59865-13-3, 63798-73-2; (deflazacort) 14484-47-0; (diclofenac) 15307-79-6, 15307-86-5; (immunoglobulin g) 97794-27-9; (leflunomide) 75706-12-6; (meloxicam) 71125-38-7; (methotrexate) 15475-56-6, 59-05-2, 7413-34-5; (minocycline) 10118-90-8, 11006-27-2, 13614-98-7; (misoprostol) 59122-46-2, 59122-48-4; (nabumetone) 42924-53-8; (rifampicin) 13292-46-1; (tenidap) 100599-27-7, 120210-48-2; (tumor necrosis factor antibody) 162774-06-3

Registry records for Embase hits printed at end

CHEMICAL NAME: Neoral

L23 ANSWER 16 OF 24 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 97156124 EMBASE
DOCUMENT NUMBER: 1997156124
TITLE: Arrival of a drug: Tenidap.
AUTHOR: Saxena S.; Singh R.
CORPORATE SOURCE: Prof. S. Saxena, Department of Medicine, MLN Medical College, Allahabad, India
SOURCE: Journal of Internal Medicine, (1997) 8/1 (27-28).
Refs: 4
ISSN: 0971-8265 CODEN: JIMEFU
COUNTRY: India
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 006 Internal Medicine
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English

CONTROLLED TERM: Medical Descriptors:
*pain: SU, surgery
alopecia: SI, side effect
article
diarrhea: SI, side effect
drug efficacy
drug information
drug mechanism
dyspepsia: SI, side effect
headache: SI, side effect
human
stomach ulcer: SI, side effect
Drug Descriptors:
*antiinflammatory agent
*tenidap: PD, pharmacology
*tenidap: DT, drug therapy
*tenidap: AE, adverse drug reaction
*tenidap: PK, pharmacokinetics
antacid agent: IT, drug interaction
cimetidine: IT, drug interaction
digoxin: IT, drug interaction
dipeptidyl carboxypeptidase inhibitor: IT, drug interaction
prednisone: IT, drug interaction
thiazide diuretic agent: IT, drug interaction
tolbutamide: IT, drug interaction

CAS REGISTRY NO.: (tenidap) **100599-27-7, 120210-48-2;** (cimetidine) 51481-61-9, 70059-30-2; (digoxin) 20830-75-5, 57285-89-9; (prednisone) 53-03-2; (tolbutamide) 473-41-6, 64-77-7

L23 ANSWER 17 OF 24 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 96043925 EMBASE
DOCUMENT NUMBER: 1996043925
TITLE: Tenidap: Not just another NSAID?.
AUTHOR: Canvin J.M.G.; Madhok R.
CORPORATE SOURCE: Centre for Rheumatic Diseases, Royal Infirmary,Glasgow, United Kingdom
SOURCE: Annals of the Rheumatic Diseases, (1996) 55/2 (79-82). ISSN: 0003-4967 CODEN: ARDIAO
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; (Short Survey)
FILE SEGMENT: 031. Arthritis and Rheumatism
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English

CONTROLLED TERM: Medical Descriptors:
*rheumatoid arthritis: DT, drug therapy
alopecia: SI, side effect
clinical trial
double blind procedure
edema: SI, side effect
gastrointestinal symptom: SI, side effect
headache: SI, side effect
human
multicenter study
priority journal
proteinuria: SI, side effect
randomized controlled trial
rash: SI, side effect
short survey

Drug Descriptors:
*auranofin: DT, drug therapy
*diclofenac: DT, drug therapy
*hydroxychloroquine: DT, drug therapy
*naproxen: DT, drug therapy
*prednisolone: DT, drug therapy
*tenidap: AE, adverse drug reaction
*tenidap: DT, drug therapy
nonsteroid antiinflammatory agent
CAS REGISTRY NO.: (auranofin) 34031-32-8; (diclofenac) 15307-79-6, 15307-86-5; (hydroxychloroquine) 118-42-3, 525-31-5; (naproxen) 22204-53-1, 26159-34-2; (prednisolone) 50-24-8; (tenidap) 100599-27-7, 120210-48-2

L23 ANSWER 18 OF 24 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 96079839 EMBASE
DOCUMENT NUMBER: 1996079839
TITLE: [Tenidap - A new antirheumatic agent].
TENIDAP, EIN NEUES ANTIRHEUMATIKUM.
AUTHOR: Uhl D.
CORPORATE SOURCE: Germany
SOURCE: Deutsche Apotheker Zeitung, (1996) 136/10 (30+32).
ISSN: 0011-9857 CODEN: DAZEA2
COUNTRY: Germany
DOCUMENT TYPE: Journal; Note
FILE SEGMENT: 031 Arthritis and Rheumatism
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: German
SUMMARY LANGUAGE: German

CONTROLLED TERM: Medical Descriptors:
*rheumatic disease: DT, drug therapy
alopecia: SI, side effect
drug efficacy
drug structure
drug tolerance
gastrointestinal symptom: SI, side effect
headache: SI, side effect
human
note
rash: SI, side effect
Drug Descriptors:
*antirheumatic agent: DT, drug therapy
*tenidap: DT, drug therapy
*tenidap: AE, adverse drug reaction
nonsteroid antiinflammatory agent: DT, drug therapy
prostaglandin synthase: EC, endogenous compound
CAS REGISTRY NO.: (tenidap) 100599-27-7, 120210-48-2; (prostaglandin synthase) 39391-18-9, 59763-19-8, 9055-65-6

L23 ANSWER 19 OF 24 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 95282162 EMBASE
DOCUMENT NUMBER: 1995282162
TITLE: Investigational agents for rheumatoid arthritis.
AUTHOR: Merkel P.A.; Letourneau E.N.; Polisson R.P.
CORPORATE SOURCE: Arthritis Unit-Bulfinch 165, Massachusetts General Hospital, 32 Fruit Street,Boston, MA 02114, United States
SOURCE: Rheumatic Disease Clinics of North America, (1995) 21/3 (779-796).
ISSN: 0889-857X CODEN: RDCAEK
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review

FILE SEGMENT: 030 Pharmacology
031 Arthritis and Rheumatism
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ABSTRACT:
Agents ranging from simple analgesics to antiinflammatory drugs to powerful immunomodulators have been used for the treatment of rheumatoid arthritis with varying success. Despite the availability of agents that are believed to be 'second line' or 'disease modifying,' many patients either do not respond adequately to available agents or must discontinue their use because of intolerable or dangerous adverse reactions. For this reason, researchers continue to search for more efficacious and less toxic agents for patients with rheumatoid arthritis. This article describes pharmaceutical agents currently under investigation for use in rheumatoid arthritis, including the antiinflammatory agents, zileuton and tenidap, and the Immunosuppressive agents, leflunomide, mycophenolic acid (RS-61443), tacrolimus (FK-506), sirolimus (rapamycin), amiprilose (therafectin), cladribine (2-chlorodeoxyadenosine), and azaribine.

CONTROLLED TERM: Medical Descriptors:
*rheumatoid arthritis: DT, drug therapy
abdominal pain: SI, side effect
alopecia: SI, side effect
arachidonic acid metabolism
chondrogenesis
clinical trial
diarrhea: SI, side effect
drug mechanism
fever: SI, side effect
gastrointestinal symptom: SI, side effect
herpes zoster: SI, side effect
human
hyperglycemia: SI, side effect
hypersensitivity: SI, side effect
intravenous drug administration
meta analysis
nephrotoxicity: SI, side effect
neurotoxicity: SI, side effect
nonhuman
oral drug administration
priority journal
proteinuria: SI, side effect
rash: SI, side effect
review
thrombosis: SI, side effect
Drug Descriptors:
*antiinflammatory agent: AE, adverse drug reaction
*antiinflammatory agent: CT, clinical trial
*antiinflammatory agent: CM, drug comparison
*antiinflammatory agent: DT, drug therapy
*antiinflammatory agent: PD, pharmacology
*antirheumatic agent: AE, adverse drug reaction
*antirheumatic agent: CT, clinical trial
*antirheumatic agent: DV, drug development
*antirheumatic agent: DT, drug therapy
*antirheumatic agent: CB, drug combination
*antirheumatic agent: CM, drug comparison
*antirheumatic agent: PD, pharmacology
*immunosuppressive agent: PD, pharmacology
*immunosuppressive agent: DV, drug development
*immunosuppressive agent: AE, adverse drug reaction

*immunosuppressive agent: CT, clinical trial
*immunosuppressive agent: DT, drug therapy
15 deoxyspergualin: DV, drug development
2 chlorodeoxyadenosine: AE, adverse drug reaction
2 chlorodeoxyadenosine: CT, clinical trial
2 chlorodeoxyadenosine: DT, drug therapy
2 chlorodeoxyadenosine: PD, pharmacology
amiprilose: CT, clinical trial
amiprilose: DT, drug therapy
amiprilose: PD, pharmacology
auranofin: DT, drug therapy
auranofin: CM, drug comparison
auranofin: CB, drug combination
azaribine: AE, adverse drug reaction
azaribine: CT, clinical trial
azaribine: DT, drug therapy
azaribine: PD, pharmacology
brequinar: DV, drug development
cyclosporin a: DT, drug therapy
cyclosporin a: CM, drug comparison
cyclosporin a derivative: DV, drug development
diclofenac: CB, drug combination
diclofenac: DT, drug therapy
diclofenac: CM, drug comparison
hydroxychloroquine: DT, drug therapy
hydroxychloroquine: CM, drug comparison
hydroxychloroquine: CB, drug combination
ibuprofen: DT, drug therapy
ibuprofen: CM, drug comparison
leflunomide: PD, pharmacology
leflunomide: DT, drug therapy
leflunomide: DV, drug development
leflunomide: CT, clinical trial
leflunomide: AE, adverse drug reaction
mizoribine: DV, drug development
mycophenolic acid 2 morpholinoethyl ester: AE, adverse drug reaction
mycophenolic acid 2 morpholinoethyl ester: DV, drug development
mycophenolic acid 2 morpholinoethyl ester: CT, clinical trial
mycophenolic acid 2 morpholinoethyl ester: PD, pharmacology
mycophenolic acid 2 morpholinoethyl ester: DT, drug therapy
nonsteroid antiinflammatory agent: CM, drug comparison
nonsteroid antiinflammatory agent: DT, drug therapy
piroxicam: CB, drug combination
piroxicam: CM, drug comparison
piroxicam: DT, drug therapy
rapamycin: PD, pharmacology
rapamycin: DV, drug development
tenidap: PD, pharmacology
tenidap: CM, drug comparison
tenidap: AE, adverse drug reaction
tenidap: CT, clinical trial
tenidap: DT, drug therapy
tsukubaenolide: CM, drug comparison
tsukubaenolide: DT, drug therapy
tsukubaenolide: PD, pharmacology
tsukubaenolide: CT, clinical trial
tsukubaenolide: AE, adverse drug reaction
zileuton: CT, clinical trial
zileuton: PD, pharmacology
zileuton: DT, drug therapy

zileuton: CM, drug comparison
CAS REGISTRY NO.: (15 deoxyspergualin) 84937-45-1; (2 chlorodeoxyadenosine) 4291-63-8; (amiprilose) 56824-20-5; (auranofin) 34031-32-8; (azaribine) 2169-64-4; (brequinar) 96187-53-0, 96201-88-6; (cyclosporin a) 59865-13-3, 63798-73-2; (diclofenac) 15307-79-6, 15307-86-5; (hydroxychloroquine) 118-42-3, 525-31-5; (ibuprofen) 15687-27-1; (leflunomide) 75706-12-6; (mizoribine) 50924-49-7; (mycophenolic acid 2 morpholinoethyl ester) 128794-94-5; (piroxicam) 36322-90-4; (rapamycin) 53123-88-9; (tenidap) 100599-27-7, 120210-48-2; (tsukubaenolide) 104987-11-3; (zileuton) 111406-87-2, 132880-11-6
CHEMICAL NAME: Tacrolimus; Therafectin; Sirolimus; Rs 61443; Sm 1213

L23 ANSWER 20 OF 24 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 95241490 EMBASE
DOCUMENT NUMBER: 1995241490
TITLE: A comparative study of tenidap, a cytokine-modulating anti-rheumatic drug, and diclofenac in rheumatoid arthritis: A 24-week analysis of a 1-year clinical trial.
AUTHOR: Wylie G.; Appelboom T.; Bolten W.; Breedveld F.C.; Feely J.; Leeming M.R.G.; Le Loet X.; Manthorpe R.; Marcolongo R.; Smolen J.
CORPORATE SOURCE: Central Research Division, Pfizer Ltd, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom
SOURCE: British Journal of Rheumatology, (1995) 34/6 (554-563). ISSN: 0263-7103 CODEN: BJRHDF
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 031 Arthritis and Rheumatism
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ABSTRACT:
Tenidap is a novel anti-rheumatic drug that combines cytokine modulation with cyclo-oxygenase inhibition. This 24-week, multicentre, double-blind, randomized study compared the clinical efficacy, biochemical effects and safety of tenidap 120 mg/day (once daily) with diclofenac 150 mg/day (50 mg t.i.d.) in the treatment of 384 patients with active rheumatoid arthritis. After 24 weeks, improvement with tenidap was significantly greater than with diclofenac for all five primary efficacy parameters, two of the four secondary efficacy parameters and 11 of the 13 Arthritis Impact Measurement Scales assessments. The superior efficacy of tenidap was apparent after 4 weeks of treatment with further improvements observed by 24 weeks. The probability of discontinuation due to lack of efficacy was significantly greater in the diclofenac group. Tenidap but not diclofenac was associated with significant, rapid and sustained reductions in C-reactive protein and serum amyloid A levels and with a significant reduction in plasma interleukin-6. The nature and frequency of side-effects were similar in the two groups as was the discontinuation rate for treatment-related safety reasons. Tenidap was associated with an equal incidence of elevated transaminases, but a higher incidence of mild (.gtoreq. 500 mg/24 h < 1500 mg/24 h) non-progressive, proteinuria of proximal tubular origin compared with diclofenac.

CONTROLLED TERM: Medical Descriptors:
*rheumatoid arthritis: DT, drug therapy
abdominal pain: SI, side effect
adult
aged
alopecia: SI, side effect
article
asthenia: SI, side effect

clinical trial
controlled study
digestive system function disorder: SI, side effect
double blind procedure
drug efficacy
drug safety
drug withdrawal
female
fever: SI, side effect
headache: SI, side effect
human
major clinical study
male
multicenter study
oral drug administration
priority journal
randomized controlled trial
rash: SI, side effect
vertigo: SI, side effect
Drug Descriptors:
*diclofenac: DT, drug therapy
*diclofenac: CM, drug comparison
*diclofenac: CT, clinical trial
*diclofenac: AE, adverse drug reaction
*tenidap: AE, adverse drug reaction
*tenidap: DT, drug therapy
*tenidap: CM, drug comparison
*tenidap: CT, clinical trial
aminotransferase: EC, endogenous compound
antirheumatic agent: AE, adverse drug reaction
antirheumatic agent: DT, drug therapy
antirheumatic agent: CT, clinical trial
c reactive protein: EC, endogenous compound
interleukin 6: EC, endogenous compound
serum amyloid a: EC, endogenous compound

CAS REGISTRY NO.: (diclofenac) 15307-79-6, 15307-86-5; (tenidap) 100599-27-7, 120210-48-2; (aminotransferase) 9031-66-7; (c reactive protein) 9007-41-4

L23 ANSWER 21 OF 24 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 95255068 EMBASE
DOCUMENT NUMBER: 1995255068
TITLE: Tenidap.
AUTHOR: Madhok R.
CORPORATE SOURCE: Centre for Rheumatic Diseases, Glasgow Royal Infirmary University, NHS Trust, 84 Castle Street,Glasgow E4 0SF, United Kingdom
SOURCE: Lancet, (1995) 346/8973 (481-485).
ISSN: 0140-6736 CODEN: LANCAO
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 006 Internal Medicine
030 Pharmacology
031 Arthritis and Rheumatism
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English

CONTROLLED TERM: Medical Descriptors:
*rheumatoid arthritis: DT, drug therapy
alopecia: SI, side effect
antiinflammatory activity

arachidonic acid metabolism
clinical trial
drug bioavailability
drug contraindication
drug efficacy
drug half life
drug mechanism
enzyme inhibition
gastrointestinal disease: SI, side effect
headache: SI, side effect
health care cost
human
hypertension: DT, drug therapy
intramuscular drug administration
life expectancy
oral drug administration
priority journal
proteinuria: SI, side effect
rash: SI, side effect
review
Drug Descriptors:
*tenidap: PK, pharmacokinetics
*tenidap: DT, drug therapy
*tenidap: PD, pharmacology
*tenidap: AE, adverse drug reaction
*tenidap: IT, drug interaction
*tenidap: CM, drug comparison
*tenidap: CT, clinical trial
auranofin: DT, drug therapy
auranofin: CM, drug comparison
auranofin: CT, clinical trial
aurothiomalate: DT, drug therapy
azathioprine: DT, drug therapy
beta adrenergic receptor blocking agent: DT, drug therapy
beta adrenergic receptor blocking agent: IT, drug interaction
beta adrenergic receptor blocking agent: PD, pharmacology
cyclosporin: DT, drug therapy
cytokine: EC, endogenous compound
gold: DT, drug therapy
hydroxychloroquine: CT, clinical trial
hydroxychloroquine: CM, drug comparison
hydroxychloroquine: DT, drug therapy
lithium: IT, drug interaction
methotrexate: DT, drug therapy
nonsteroid antiinflammatory agent: DT, drug therapy
penicillamine: DT, drug therapy
phenytoin: IT, drug interaction
piroxicam: CM, drug comparison
piroxicam: CT, clinical trial
piroxicam: DT, drug therapy
prostaglandin synthase: EC, endogenous compound
salazosulfapyridine: DT, drug therapy
thiazide diuretic agent: IT, drug interaction
thiazide diuretic agent: DT, drug therapy
thiazide diuretic agent: PD, pharmacology
warfarin: IT, drug interaction

CAS REGISTRY NO.: (tenidap) 100599-27-7, 120210-48-2; (auranofin) 34031-32-8; (aurothiomalate) 12244-57-4; (azathioprine) 446-86-6; (cyclosporin) 79217-60-0; (gold) 7440-57-5; (hydroxychloroquine) 118-42-3, 525-31-5; (lithium) 7439-93-2; (methotrexate) 15475-56-6, 59-05-2, 7413-34-5; (penicillamine) 2219-30-9, 52-67-5; (phenytoin)

57-41-0, 630-93-3; (piroxicam) 36322-90-4; (prostaglandin synthase) 39391-18-9, 59763-19-8, 9055-65-6; (salazosulfapyridine) 599-79-1; (warfarin) 129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2

L23 ANSWER 22 OF 24 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 94056346 EMBASE
DOCUMENT NUMBER: 1994056346
TITLE: Clinical pharmacology and modification of autoimmunity and inflammation in rheumatoid disease.
AUTHOR: Luqmani R.; Gordon C.; Bacon P.
CORPORATE SOURCE: Department of Rheumatology, University of Birmingham, Vincent Drive,Edgbaston, Birmingham B15 2TT, United Kingdom
SOURCE: Drugs, (1994) 47/2 (259-285).
ISSN: 0012-6667 CODEN: DRUGAY
COUNTRY: New Zealand
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 026 Immunology, Serology and Transplantation
030 Pharmacology
031 Arthritis and Rheumatism
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ABSTRACT:
The increased understanding of the mechanisms which underlie rheumatoid disease has been accompanied by a more appropriate use of the limited repertoire of therapeutic agents. Conventional second-line drugs still have a role in everyday practice. The efficacy of these agents in reducing the severity of clinical signs of joint inflammation, whilst at the same time causing significant reductions in the laboratory measures of the acute phase response is undoubtedly confirmed by meta-analysis of several therapeutic trials of these agents. Whether or not these agents can influence outcome, usually assessed in terms of radiological progression, is more contentious. Furthermore, their toxicity in long term use is not inconsiderable. However, newer agents may play a more important part in therapy in the future. Such therapy can be designed to specifically interfere with the abnormalities of the immune system which characterise rheumatoid arthritis. Many of the agents reviewed have been successfully applied to animal models of arthritis, but we still await large randomised controlled studies in humans to determine their clinical effiency and toxicity. In view of the complexity of the immunological abnormalities in rheumatoid arthritis, it may be necessary to consider using a number of such agents in any particular patient. This should result in more rational therapy in rheumatoid arthritis.

CONTROLLED TERM: Medical Descriptors:
*autoimmunity
*inflammation: TH, therapy
*inflammation: DT, drug therapy
*rheumatic disease: TH, therapy
*rheumatic disease: DT, drug therapy
alopecia: SI, side effect
animal experiment
animal model
antiinflammatory activity
apheresis
blood dyscrasia: SI, side effect
bone erosion: PC, prevention
bone erosion: DT, drug therapy
bone marrow suppression: SI, side effect
carcinogenesis: SI, side effect
clinical pharmacology
clinical trial

dna synthesis
drug absorption
drug elimination
heart infarction: SI, side effect
human
immune system
intramuscular drug administration
intravenous drug administration
major histocompatibility complex
meta analysis
mouse
myelodysplasia: SI, side effect
necrotizing arteritis: DT, drug therapy
nephrotoxicity: SI, side effect
nonhuman
oral drug administration
pneumonia: SI, side effect
review
rheumatoid arthritis: DT, drug therapy
sister chromatid exchange
stomatitis: SI, side effect
synovitis: DT, drug therapy
t lymphocyte
teratogenesis
thrombocytopenia: SI, side effect
urticaria: SI, side effect
vasculitis: DT, drug therapy
therapy
drug therapy
Drug Descriptors:
acetylsalicylic acid: CM, drug comparison
acetylsalicylic acid: DT, drug therapy
aminoglycoside: IT, drug interaction
antacid agent: IT, drug interaction
antimalarial agent: CB, drug combination
antimalarial agent: DT, drug therapy
antimalarial agent: PK, pharmacokinetics
auranofin: DT, drug therapy
auranofin: CB, drug combination
auranofin: CM, drug comparison
azathioprine: PD, pharmacology
azathioprine: DT, drug therapy
azathioprine: CM, drug comparison
azathioprine: CB, drug combination
azathioprine: AE, adverse drug reaction
cd4 antigen: EC, endogenous compound
chimeric protein: DV, drug development
chlorambucil: AE, adverse drug reaction
chlorambucil: DT, drug therapy
chlorambucil: PK, pharmacokinetics
chlorambucil: PD, pharmacology
chloroquine: DT, drug therapy
corticosteroid: PK, pharmacokinetics
corticosteroid: CM, drug comparison
corticosteroid: DT, drug therapy
cyclophosphamide: AE, adverse drug reaction
cyclophosphamide: CB, drug combination
cyclophosphamide: DT, drug therapy
cyclophosphamide: PK, pharmacokinetics
cyclosporin: AE, adverse drug reaction
cyclosporin: PD, pharmacology
cyclosporin: DT, drug therapy
cytokine: EC, endogenous compound

gamma interferon: DT, drug therapy
gamma interferon: CT, clinical trial
gold salt: DT, drug therapy
gold salt: CM, drug comparison
gold salt: CB, drug combination
hybrid protein: DT, drug therapy
hydroxychloroquine: DT, drug therapy
immunoglobulin: PD, pharmacology
immunoglobulin: DT, drug therapy
interleukin 2 receptor: EC, endogenous compound
methotrexate: PD, pharmacology
methotrexate: CM, drug comparison
methotrexate: IT, drug interaction
methotrexate: DT, drug therapy
methotrexate: AE, adverse drug reaction
methotrexate: CB, drug combination
monoclonal antibody: DT, drug therapy
neomycin: IT, drug interaction
okt 4: CT, clinical trial
okt 4: AE, adverse drug reaction
okt 4: DV, drug development
penicillamine: PK, pharmacokinetics
penicillamine: AE, adverse drug reaction
penicillamine: DT, drug therapy
penicillamine: IT, drug interaction
peptide: DV, drug development
peptide: PD, pharmacology
prednisolone: CM, drug comparison
prednisolone: CB, drug combination
prednisolone: DT, drug therapy
prednisolone: PK, pharmacokinetics
salazosulfapyridine: DT, drug therapy
salazosulfapyridine: AE, adverse drug reaction
salazosulfapyridine: PK, pharmacokinetics
tenidap: DT, drug therapy
unindexed drug

CAS REGISTRY NO.: (acetylsalicylic acid) 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; (auranofin) 34031-32-8; (azathioprine) 446-86-6; (chlorambucil) 305-03-3; (chloroquine) 132-73-0, 3545-67-3, 50-63-5, 54-05-7; (cyclophosphamide) 50-18-0; (cyclosporin) 79217-60-0; (gamma interferon) 82115-62-6; (hydroxychloroquine) 118-42-3, 525-31-5; (immunoglobulin) 9007-83-4; (methotrexate) 15475-56-6, 59-05-2, 7413-34-5; (neomycin) 11004-65-2, 1404-04-2, 1405-10-3, 8026-22-0; (penicillamine) 2219-30-9, 52-67-5; (prednisolone) 50-24-8; (salazosulfapyridine) 599-79-1; (tenidap) 100599-27-7, 120210-48-2

L23 ANSWER 23 OF 24 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 95051508 EMBASE
DOCUMENT NUMBER: 1995051508
TITLE: Tenidap: A novel cytokine-modulating antirheumatic drug for the treatment of rheumatoid arthritis.
AUTHOR: Breedveld F.
CORPORATE SOURCE: Department of Rheumatology, University Hospital Leiden, Netherlands
SOURCE: Scandinavian Journal of Rheumatology, Supplement, (1994) 23/100 (31-44).
ISSN: 0301-3847 CODEN: SJRSAS
COUNTRY: Norway
DOCUMENT TYPE: Journal; Conference Article
FILE SEGMENT: 031 Arthritis and Rheumatism

037 Drug Literature Index
038 Adverse Reactions Titles

LANGUAGE: English
SUMMARY LANGUAGE: English
ABSTRACT:

Tenidap is a novel, once-daily, cytokine modulating antirheumatic drug indicated for the treatment of rheumatoid arthritis (RA). In vitro, tenidap significantly inhibits the production of the pro-inflammatory cytokines, interleukin-1, interleukin-6 and tumour necrosis factor in human cell lines, and inhibits cytokine-mediated processes such as cartilage degradation, bone resorption, metalloprotease synthesis, endothelial cell adhesion and monocyte differentiation. Tenidap also inhibits cyclo-oxygenase. In RA patients, tenidap 120 mg/day is clinically equivalent to the combination of disease-modifying antirheumatic agents plus non-steroidal anti-inflammatory drugs (NSAIDs) and significantly more effective than NSAIDs. Tenidap also produces rapid, profound and sustained reductions in the serum levels of the acute phase proteins, C-reactive protein and serum amyloid A, an effect suggestive of disease modifying properties. In addition, tenidap reduces circulating levels of IL-6 in RA patients. Tenidap is well tolerated.

CONTROLLED TERM: Medical Descriptors:
*rheumatoid arthritis: DT, drug therapy
abdominal pain: SI, side effect
alopecia: SI, side effect
anorexia: SI, side effect
antiinflammatory activity
asthenia: SI, side effect
cartilage degeneration
cell adhesion
clinical trial
conference paper
constipation: SI, side effect
diarrhea: SI, side effect
double blind procedure
drug efficacy
drug tolerance
dyspepsia: SI, side effect
endothelium cell
flatulence: SI, side effect
gastroduodenal ulcer: SI, side effect
headache: SI, side effect
human
monocyte
multicenter study
nausea: SI, side effect
osteolysis
priority journal
randomized controlled trial
rash: SI, side effect
stomatitis: SI, side effect
vertigo: SI, side effect
vomiting: SI, side effect
Drug Descriptors:
*tenidap: AE, adverse drug reaction
*tenidap: DT, drug therapy
*tenidap: CB, drug combination
*tenidap: CT, clinical trial
acute phase protein: EC, endogenous compound
auranofin: CB, drug combination
auranofin: CT, clinical trial
auranofin: DT, drug therapy
c reactive protein: EC, endogenous compound
diclofenac: CB, drug combination

diclofenac: CT, clinical trial
diclofenac: DT, drug therapy
hydroxychloroquine: DT, drug therapy
hydroxychloroquine: CT, clinical trial
hydroxychloroquine: CB, drug combination
interleukin 1: EC, endogenous compound
interleukin 6: EC, endogenous compound
metalloproteinase: EC, endogenous compound
naproxen: DT, drug therapy
naproxen: CB, drug combination
naproxen: CT, clinical trial
nonsteroid antiinflammatory agent: DT, drug therapy
nonsteroid antiinflammatory agent: AE, adverse drug reaction
piroxicam: CT, clinical trial
piroxicam: DT, drug therapy
piroxicam: CB, drug combination
prostaglandin synthase: EC, endogenous compound
serum amyloid a: EC, endogenous compound
tumor necrosis factor: EC, endogenous compound

CAS REGISTRY NO.: (tenidap) **100599-27-7, 120210-48-2;** (auranofin) 34031-32-8; (c reactive protein) 9007-41-4; (diclofenac) 15307-79-6, 15307-86-5; (hydroxychloroquine) 118-42-3, 525-31-5; (metalloproteinase) 81669-70-7; (naproxen) 22204-53-1, 26159-34-2; (piroxicam) 36322-90-4; (prostaglandin synthase) 39391-18-9, 59763-19-8, 9055-65-6

L23 ANSWER 24 OF 24 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 92247095 EMBASE
DOCUMENT NUMBER: 1992247095
TITLE: Intervention with immunomodulatory agents: New pharmacological developments.
AUTHOR: Veys E.M.; Mielants H.; Verbruggen G.; De Keyser F.
CORPORATE SOURCE: Department of Rheumatology, University Hospital, De Pintelaan 185,B-9000 Ghent, Belgium
SOURCE: Bailliere's Clinical Rheumatology, (1992) 6/2 (455-484). ISSN: 0950-3579 CODEN: BCRHEZ
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 031 Arthritis and Rheumatism
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English

CONTROLLED TERM: Medical Descriptors:
*immunomodulation
*rheumatoid arthritis: TH, therapy
*rheumatoid arthritis: ET, etiology
*rheumatoid arthritis: DT, drug therapy
autoimmunity
cell activity
dose response
gastrointestinal symptom: SI, side effect
gingiva hypertrophy: SI, side effect
human
hypertension: SI, side effect
hypertrichosis: SI, side effect
immunopathogenesis
intravenous drug administration
kidney disease: SI, side effect
nonhuman
paresthesia: SI, side effect
priority journal

review
suppressor cell
t lymphocyte
etiology
therapy
Drug Descriptors:
*om 89: DT, drug therapy
*om 89: PD, pharmacology
2 (3 dimethylaminopropyl) 8,8 dipropyl 2 azaspiro[4.5]decane: PD, pharmacology
cyclosporin a: PD, pharmacology
cyclosporin a: DT, drug therapy
cyclosporin a: AE, adverse drug reaction
cytokine: EC, endogenous compound
gamma interferon: EC, endogenous compound
hormone: EC, endogenous compound
immunoglobulin: DT, drug therapy
[10 methoxy 4h benzo[4,5]cyclohepta[1,2 b]thiophen 4 ylidene]acetic acid: PD, pharmacology
levamisole: PD, pharmacology
mycophenolic acid: PD, pharmacology
mycophenolic acid 2 morpholinoethyl ester: PD, pharmacology
sex hormone: EC, endogenous compound
tenidap: DT, drug therapy
tenidap: PD, pharmacology
thymulin: DT, drug therapy
thymus hormone: DT, drug therapy

CAS REGISTRY NO.: (om 89) 117989-72-7; (2 (3 dimethylaminopropyl) 8,8 dipropyl 2 azaspiro[4.5]decane) 123018-34-8; (cyclosporin a) 59865-13-3, 63798-73-2; (gamma interferon) 82115-62-6; (immunoglobulin) 9007-83-4; ([10 methoxy 4h benzo[4,5]cyclohepta[1,2 b]thiophen 4 ylidene]acetic acid) 98320-39-9; (levamisole) 14769-73-4, 16595-80-5; (mycophenolic acid) 23047-11-2, 24280-93-1; (mycophenolic acid 2 morpholinoethyl ester) 128794-94-5; (tenidap) 100599-27-7, 120210-48-2; (thymulin) 78922-62-0

CHEMICAL NAME: Cp 66248; Rs 61443; Om 8980; Ix 207887; Skf 105685

=> fil reg
FILE 'REGISTRY' ENTERED AT 15:23:42 ON 23 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 APR 2003 HIGHEST RN 503805-80-9
DICTIONARY FILE UPDATES: 22 APR 2003 HIGHEST RN 503805-80-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

```
=> s  100599-27-7 or 120210-48-2

             1 100599-27-7
               (100599-27-7/RN)
             1 120210-48-2
               (120210-48-2/RN)
L24          2 100599-27-7 OR 120210-48-2

=> d ide 1-2

L24  ANSWER 1 OF 2  REGISTRY  COPYRIGHT 2003 ACS
RN   120210-48-2  REGISTRY
CN   1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-3-(hydroxy-2-
     thienylmethylene)-2-oxo-, (3Z)- (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-3-(hydroxy-2-
     thienylmethylene)-2-oxo-, (Z)-
OTHER NAMES:
CN   CP 66248
CN   Tenidap
FS   STEREOSEARCH
MF   C14 H9 Cl N2 O3 S
CI   COM
SR   CA
LC   STN Files:   ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOBUSINESS,
       BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS,
       CIN, DDFU, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE,
       MRCK*, PROMT, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
         (*File contains numerically searchable property data)

Double bond geometry as shown.
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

             158 REFERENCES IN FILE CA (1962 TO DATE)
               7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
             158 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L24  ANSWER 2 OF 2  REGISTRY  COPYRIGHT 2003 ACS
RN   100599-27-7  REGISTRY
CN   1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-2-oxo-3-(2-thienylcarbonyl)-
     (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   5-Chloro-3-(2-thenoyl)-2-oxindole-1-carboxamide
```

FS 3D CONCORD
MF C14 H9 Cl N2 O3 S
CI COM
SR CA
LC STN Files: ADISINSIGHT, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, DDFU, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, PHAR, RTECS*, SPECINFO, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

17 REFERENCES IN FILE CA (1962 TO DATE)
17 REFERENCES IN FILE CAPLUS (1962 TO DATE)

```
=> fil reg; d stat que l28; d que nos l29
FILE 'REGISTRY' ENTERED AT 15:28:39 ON 23 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   22 APR 2003  HIGHEST RN 503805-80-9
DICTIONARY FILE UPDATES:  22 APR 2003  HIGHEST RN 503805-80-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

L26                 STR
```



claim 22

← structure of minoxidil

family search done to retrieve salts, stereoisomers, multi-component substances, and isotopically labelled forms.

```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  15

STEREO ATTRIBUTES: NONE
L28             88 SEA FILE=REGISTRY FAM FUL L26

100.0% PROCESSED    110 ITERATIONS                    88 ANSWERS
SEARCH TIME: 00.00.01


L4                  STR
L6            1165 SEA FILE=REGISTRY SSS FUL L4
L26                 STR
L28             88 SEA FILE=REGISTRY FAM FUL L26
L29              1 SEA FILE=REGISTRY ABB=ON L6 AND L28
```

structure of claims + minoxidil in same Reg. Entry record

```
=> fil capl; d que nos l30; d que nos l32; s (l30 or l32) not l15
```

FILE 'CAPLUS' ENTERED AT 15:28:40 ON 23 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 23 Apr 2003 VOL 138 ISS 17
FILE LAST UPDATED: 22 Apr 2003 (20030422/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
L4              STR
L6          1165 SEA FILE=REGISTRY SSS FUL L4
L26             STR
L28           88 SEA FILE=REGISTRY FAM FUL L26
L29            1 SEA FILE=REGISTRY ABB=ON  L6 AND L28
L30            1 SEA FILE=CAPLUS ABB=ON  L29
```

```
L4              STR
L6          1165 SEA FILE=REGISTRY SSS FUL L4
L7           255 SEA FILE=CAPLUS ABB=ON  L6
L26             STR
L28           88 SEA FILE=REGISTRY FAM FUL L26
L31          907 SEA FILE=CAPLUS ABB=ON  L28
L32            4 SEA FILE=CAPLUS ABB=ON  L31 AND L7
```

```
L37            1 (L30 OR L32) NOT L15
```

previously printed

```
=> d ibib abs hitstr 137
```

L37 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:453996 CAPLUS
DOCUMENT NUMBER: 135:266632
TITLE: Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors
AUTHOR(S): Zhao, Yuan H.; Le, Joelle; Abraham, Michael H.; Hersey, Anne; Eddershaw, Peter J.; Luscombe, Chris N.; Boutina, Darko; Beck, Gordon; Sherborne, Brad; Cooper, Ian; Platts, James A.
CORPORATE SOURCE: Department of Chemistry, University College London, London, WC1H 0AJ, UK
SOURCE: Journal of Pharmaceutical Sciences (2001), 90(6), 749-784

Searched by Barb O'Bryen, STIC 308-4291

CODEN: JPMSAE; ISSN: 0022-3549
PUBLISHER: Wiley-Liss, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The human intestinal absorption of 241 drugs was evaluated. Three main methods were used to det. the human intestinal absorption: bioavailability, percentage of urinary excretion of drug-related material following oral administration, and the ratio of cumulative urinary excretion of drug-related material following oral and i.v. administration. The general solvation equation developed by Abraham's group was used to model the human intestinal absorption data of 169 drugs we considered to have reliable data. The model contains five Abraham descriptors calcd. by the ABSOLV program. The results show that Abraham descriptors can successfully predict human intestinal absorption if the human absorption data is carefully classified based on soly. and administration dose to humans.

IT **38304-91-5**, Minoxidil **120210-48-2**, Tenidap
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(evaluation of human intestinal drug absorption data and subsequent derivation of QSAR with the Abraham descriptors)

RN 38304-91-5 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide (9CI) (CA INDEX NAME)



RN 120210-48-2 CAPLUS
CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 270 THERE ARE 270 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> fil uspatf; d que nos 134; s 134 not 119
FILE 'USPATFULL' ENTERED AT 15:31:09 ON 23 APR 2003

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 22 Apr 2003 (20030422/PD)
FILE LAST UPDATED: 22 Apr 2003 (20030422/ED)
HIGHEST GRANTED PATENT NUMBER: US6553568
HIGHEST APPLICATION PUBLICATION NUMBER: US2003074707
CA INDEXING IS CURRENT THROUGH 22 Apr 2003 (20030422/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 22 Apr 2003 (20030422/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2003
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2003

>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate substance identification.

L4 STR
L6 1165 SEA FILE=REGISTRY SSS FUL L4
L16 85 SEA FILE=USPATFULL ABB=ON L6
L26 STR
L28 88 SEA FILE=REGISTRY FAM FUL L26
L33 348 SEA FILE=USPATFULL ABB=ON L28
L34 2 SEA FILE=USPATFULL ABB=ON L33 AND L16

L39 0 L34 NOT L19 previously printed

=> fil medl drugu biosis toxcenter embase;d que nos 136; fil hom
FILE 'MEDLINE' ENTERED AT 15:31:20 ON 23 APR 2003

FILE 'DRUGU' ENTERED AT 15:31:20 ON 23 APR 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'BIOSIS' ENTERED AT 15:31:20 ON 23 APR 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'TOXCENTER' ENTERED AT 15:31:20 ON 23 APR 2003
COPYRIGHT (C) 2003 ACS

FILE 'EMBASE' ENTERED AT 15:31:20 ON 23 APR 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

L4 STR

```
L6          1165 SEA FILE=REGISTRY SSS FUL L4
L20          688 SEA L6
L26              STR
L28           88 SEA FILE=REGISTRY FAM FUL L26
L35         7095 SEA L28
L36            0 SEA L20 AND L35
```

FILE 'HOME' ENTERED AT 15:31:21 ON 23 APR 2003